Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Citation metadata

From: The New England Journal of Medicine(Vol. 362, Issue 24)
Publisher: Massachusetts Medical Society
Document Type: Clinical report
Length: 55 words

Document controls

Main content

Abstract :

A study was conducted to evaluate and compare the efficacy and safety of nilotinib as against imatinib for the treatment of newly diagnosed chronic myeloid leukemia. Results indicated that nilotinib at a dosage of 300 mg or 400 mg twice a day was found to be far more effective in the treatment of such patients.

Source Citation

Source Citation   

Gale Document Number: GALE|A233088860